May 2024 FDA Recall Tivicay by Glaxosmithkline Llc
D-0544-2024 - Labeling

This Class III drug recall was voluntarily initiated by Glaxosmithkline Llc on May 17, 2024 for the product Tivicay. The FDA reported the reason for recall as labeling. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0544-2024

Reason for Recall
Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.
Initiated
05-17-2024
Reported
06-12-2024
Quantity
463 Cartons

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Nationwide within the United States
Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottle of 60 tablets, one 30-mL dosing cup and one 10-mL oral dosing syringe, Rx Only, Mfd for: ViiV Healthcare Durham, NC, 27701, By: GlaxoSmithKline Durham, NC 27701, NDC 49702-255-37

Batch or Lot Expiration Information

Lot# : AG4M, Labeled Expiry date on carton May 2026, correct Exp. Date 04/2025